Financial News

What You Need to Know Ahead of ResMed's Earnings Release

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

ResMed Inc. (RMD), headquartered in San Diego, California, manufactures, distributes, and markets medical devices and cloud-based software applications. Valued at $35.7 billion by market cap, the company offers a range of products for respiratory disorders, including diagnostic tools like ApneaLink Air and NightOwl, cloud-based platforms like AirView and myAir for patient monitoring, and U-Sleep for HME providers, connectivity solutions, as well as out-of-hospital software solutions. The sleep tech giant is expected to announce its fiscal second-quarter earnings for 2026 in the near future. 

Ahead of the event, analysts expect RMD to report a profit of $2.68 per share on a diluted basis, up 10.3% from $2.43 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports. 

 

For the full year, analysts expect RMD to report EPS of $10.84, up 13.5% from $9.55 in fiscal 2025. Its EPS is expected to rise 9.1% year over year to $11.83 in fiscal 2027. 

www.barchart.com

RMD stock has underperformed the S&P 500 Index’s ($SPX) 16.9% gains over the past 52 weeks, with shares up 7.2% during this period. Similarly, it underperformed the Health Care Select Sector SPDR Fund’s (XLV) 13% returns over the same time frame.

www.barchart.com

On Oct. 30, RMD shares closed down marginally after reporting its Q1 results. Its adjusted EPS of $2.55 surpassed Wall Street expectations of $2.49. The company’s revenue was $1.34 billion, topping Wall Street forecasts of $1.32 billion.

Analysts’ consensus opinion on RMD stock is moderately bullish, with a “Moderate Buy” rating overall. Out of 19 analysts covering the stock, eight advise a “Strong Buy” rating, two suggest a “Moderate Buy,” eight give a “Hold,” and one recommends a “Strong Sell.” RMD’s average analyst price target is $289.38, indicating a potential upside of 18.2% from the current levels. 


On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  254.94
-7.43 (-2.83%)
AAPL  345.25
+1.26 (0.37%)
AMD  524.52
-28.20 (-5.10%)
BAC  50.98
+0.20 (0.39%)
GOOG  326.17
-4.78 (-1.44%)
META  650.45
-47.07 (-6.75%)
MSFT  529.45
-3.50 (-0.66%)
NVDA  217.80
-4.17 (-1.88%)
ORCL  127.14
-1.98 (-1.54%)
TSLA  379.62
-6.85 (-1.77%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback